New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors

Current Pharmaceutical Design

Volumn 18, Issue 20, 2012, Pages 2936-2945

  Lamba, Vandana ^a   Ghosh, Indraneel ^a  

^a University of Arizona   (United States)

Author keywords

Bisubstrate; Bivalent; Inhibitors; Protein kinase

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; BISUBSTRATE ANALOG INHIBITOR; BIVALENT INHIBITOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASEIN KINASE I; CASEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; INSULIN RECEPTOR KINASE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NILOTINIB; PD 334581; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE I INHIBITOR; PROTEIN KINASE II INHIBITOR; PROTEIN KINASE III INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN KINASE IV INHIBITOR; PROTEIN KINASE V INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 84861722034     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800672813     Document Type: Review

References (80)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
2. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-2.
3. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007; 17: 60-5.
4. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-49.
5. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian-cells by constitutively active MAP kinase kinase. Science 1994; 265: 966-70.
6. Johnson LN. The regulation of protein phosphorylation. Biochem Soc Trans 2009; 37: 627-41.
7. Cohen P. The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem Sci 2000; 25: 596-601.
8. Ubersax JA, Ferrell Jr JE. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 2007; 8: 530-41.
9. Tarrant MK, Cole PA. The chemical biology of protein phosphorylation. Annu Rev Biochem 2009; 78: 797-825.
10. Fedorov O, Mueller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010; 6: 166-9.
11. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Acc Chem Res 2003; 36: 462-9.
12. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.
13. Gray NS, Wodicka L, Thunnissen A, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998; 281: 533-8.
14. Chen J, Zhang Z, Stebbins JL, et al. A fragment-based approach for the discovery of isoform-specific p38 alpha inhibitors. ACS Chem Biol 2007; 2: 329-36.
15. Toledo LM, Lydon NB, Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 1999; 6: 775-805.
16. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
17. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-36.
18. Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1046-51.
19. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011; 29: 1039-45.
20. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10: 130-7.
21. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-51.
22. Gupta R, Maitland M. Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity. Curr Hypertens Rep 2011; 13: 430-5.
23. Cox KJ, Shomin CD, Ghosh I. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Med Chem 2011; 3: 29-43.
24. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005; 12: 621-37.
25. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
26. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-42.
27. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-43.
28. Pargellis C, Tong L, Churchill L, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Mol Biol 2002; 9: 268-72.
29. Wan PTC, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell 2004; 116: 855-67.
30. Manley PW, Bold G, Brüggen J, et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim Biophys Acta 2004; 1697: 17-27.
31. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2: 358-64.
32. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-56.
33. Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315l: from the second to third generation. Expert Rev Anticancer Ther 2008; 8: 1387-98.
34. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-7.
35. Feramisco JR, Krebs EG. Inhibition of cyclic AMP-dependent protein kinase by analogues of a synthetic peptide substrate. J Biol Chem 1978; 253: 8968-71.
36. Ye GF, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs 2008; 9: 605-13.
37. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002; 109: 275-82.
38. Shi Z, Resing KA, Ahn NG. Networks for the allosteric control of protein kinases. Curr Opin Struct Biol 2006; 16: 686-92.
39. Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005; 385: 399-408.
40. Wu W-I, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS ONE 2010; 5: e12913.
41. Adrian FJ, Ding Q, Sim T, et al. Allosteric inhibitors of Bcr-abldependent cell proliferation. Nat Chem Biol 2006; 2: 95-102.
42. Converso A, Hartingh T, Garbaccio RM, et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009; 19: 1240-4.
43. Biondi RM, Cheung PCF, Casamayor A, Deak M, Currie RA, Alessi DR. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 2000; 19: 979-88.
44. Bobkova EV, Weber MJ, Xu Z, et al. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. J Biol Chem 2010; 285: 18838-46.
45. Nigg EA. Cyclin-dependent protein-kinases-key regulators of the eukaryotic cell-cycle. Bioessays 1995; 17: 471-80.
46. Betzi S, Alam R, Martin M, et al. Discovery of a potential allosteric ligand binding site in CDK2. ACS Chem Biol 2011; 6: 492-501.
47. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007; 450: 741-4.
48. Fry DC. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pep Sci 2008; 9: 240-7.
49. Wilson AJ. Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev 2009; 38: 3289-300.
50. Hershberger SJ, Lee SG, Chmielewski J. Scaffolds for blocking protein-protein interactions. Curr Top Med Chem 2007; 7: 928-42.
51. Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opin Chem Biol 2009; 13: 284-90.
52. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004; 3: 301-17.
53. Parang K, Cole PA. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 2002; 93: 145-57.
54. Jencks WP. On the attribution and additivity of binding energies. Proc Natl Acad Sci 1981; 78: 4046-50.
55. Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA. Mechanism-based design of a protein kinase inhibitor. Nat Struct Mol Biol 2001; 8: 37-41.
56. Hines AC, Cole PA. Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A. Bioorg Med Chem Lett 2004; 14: 2951-4.
57. Ahn D-R, Han K-C, Kwon HS, Yang EG. ATP-conjugated peptide inhibitors for calmodulin-dependent protein kinase II. Bioorg Med Chem Lett 2007; 17: 147-51.
58. Kumar A, Wang Y, Lin X, Sun G, Parang K. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. ChemMedChem 2007; 2: 1346-60.
59. Ricouart A, Gesquiere JC, Tartar A, Sergheraert C. Design of potent protein kinases inhibitors using the bisubstrate approach. J Med Chem 1991; 34: 73-8.
60. Loog M, Uri A, Raidaru G, Järv J, Ek P. Adenosine-5 carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett 1999; 9: 1447-52.
61. Lavogina D, Enkvist E, Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem 2010; 5: 23-34.
62. Enkvist E, Lavogina D, Raidaru G, et al. Conjugation of adenosine and hexa-(d-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J Med Chem 2006; 49: 7150-9.
63. Lavogina D, Lust M, Viil I, et al. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J Med Chem 2009; 52: 308-21.
64. Schneider TL, Mathew RS, Rice KP, Tamaki K, Wood JL, Schepartz A. Increasing the kinase specificity of K252a by protein surface recognition. Org Lett 2005; 7: 1695-8.
65. Lee JH, Kumar S, Lawrence DS. Stepwise combinatorial evolution of Akt bisubstrate inhibitors. ChemBioChem 2008; 9: 507-9.
66. Profit AA, Lee TR, Lawrence DS. Bivalent inhibitors of protein tyrosine kinases. J Am Chem Soc 1999; 121: 280-3.
67. Hah J-M, Sharma V, Li H, Lawrence DS. Acquisition of a "Group A"-selective Src kinase inhibitor via a global targeting strategy. J Am Chem Soc 2006; 128: 5996-7.
68. Nam NH, Lee SS, Ye GF, Sun GQ, Parang K. ATPphosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg Med Chem 2004; 12: 5753-66.
69. Stebbins JL, De SK, Pavlickova P, et al. Design and characterization of a potent and selective dual ATP-and substratecompetitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J Med Chem 2011; 54: 6206-14.
70. Hill ZB, Perera BGK, Maly DJ. A chemical genetic method for generating bivalent inhibitors of protein kinases. J Am Chem Soc 2009; 131: 6686-8.
71. Hinner MJ, Johnsson K. How to obtain labeled proteins and what to do with them. Curr Opin Biotechnol 2010; 21: 766-76.
72. Hill ZB, Perera BGK, Maly DJ. Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. Mol Biosyst 2011; 7: 447-56.
73. Hill ZB, Perera BGK, Andrews SS, Maly DJ. Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. ACS Chem Biol 2011.
74. Meyer SC, Shomin CD, Gaj T, Ghosh I. Tethering small molecules to a phage display library: Discovery of a selective bivalent inhibitor of protein kinase A. J Am Chem Soc 2007; 129: 13812-3.
75. Shomin CD, Meyer SC, Ghosh I. Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): Optimization and selectivity profiling. Bioorg Med Chem 2009; 17: 6196-202.
76. Jester BW, Cox KJ, Gaj A, Shomin CD, Porter JR, Ghosh I. A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. J Am Chem Soc 2010; 132: 11727-35.
77. Krishnamurty R, Maly DJ. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity. Comb Chem High Throughput Screen 2007; 10: 652-66.
78. Tokumitsu H, Chijiwa T, Hagiwara M, Mizutani A, Terasawa M, Hidaka H. KN-62,1-N, O-bis(5-isoquinolinesulfonyl)-N-methyl-Ltyrosyl-4-Phenylpiperazine, a specific inhibitor of Ca-2+/Calmodulin-dependent protein kinase-II. J Biol Chem 1990; 265: 4315-20.
79. Shomin CD, Restituyo E, Cox KJ, Ghosh I. Selection of cyclicpeptide inhibitors targeting Aurora kinase A: Problems and solutions. Bioorg Med Chem 2011; 19: 6743-9.
80. Fujiwara D, Ye Z, Gouda M, Yokota K, Tsumuraya T, Fujii I. Selection of inhibitory peptides for Aurora-A kinase from a phagedisplayed library of helix-loop-helix peptides. Bioorg Med Chem Lett 2010; 20: 1776-8.